📷 Image: Wikimedia Commons / Vyacheslav Argenberg
Health
Maharashtra FDA Reverses Cancellation of Cipla Drug Licence
✍️ Free Press Journal
🗓 30 Aug 2026, 07:04 AM
👁 4
The Maharashtra Food and Drug Administration has withdrawn its earlier order to cancel the licence of a Cipla drug, restoring its market status.
The state Food and Drug Administration (FDA) of Maharashtra announced that it has rescinded its previous decision to cancel the licence of a specific Cipla pharmaceutical product. The reversal comes after a review of the regulatory compliance documents submitted by the company, which reportedly satisfied the agency's safety and quality standards.
Officials said the original cancellation order, issued earlier this month, was based on preliminary concerns about manufacturing practices. However, subsequent inspections and additional data provided by Cipla clarified the issues, leading the FDA to restore the licence without any penalty.
The decision has been welcomed by industry observers, who noted that maintaining the drug's availability is crucial for patients who rely on it for chronic conditions. The FDA also affirmed that it will continue to monitor the product to ensure ongoing compliance with state regulations.
Cipla has not issued a detailed statement yet, but sources close to the company indicated that the reversal will help avoid potential supply disruptions and protect its market share in the region.
Officials said the original cancellation order, issued earlier this month, was based on preliminary concerns about manufacturing practices. However, subsequent inspections and additional data provided by Cipla clarified the issues, leading the FDA to restore the licence without any penalty.
The decision has been welcomed by industry observers, who noted that maintaining the drug's availability is crucial for patients who rely on it for chronic conditions. The FDA also affirmed that it will continue to monitor the product to ensure ongoing compliance with state regulations.
Cipla has not issued a detailed statement yet, but sources close to the company indicated that the reversal will help avoid potential supply disruptions and protect its market share in the region.